# NICE Type 2 Diabetes in Adults (NG28)

Specialty: EndocrinologyAgent
Source URL: https://www.nice.org.uk/guidance/ng28
Fetched At: 2026-02-22T22:46:21Z

---

Overview | Type 2 diabetes in adults: management | Guidance | NICE You are here: Home NICE Guidance Conditions and diseases Diabetes and other endocrinal, nutritional and metabolic conditions Diabetes Type 2 diabetes in adults: management NICE guideline Reference number: NG28 Published: 02 December 2015 Last updated: 18 February 2026 Guidance Tools and resources Information for the public Evidence History Download guidance (PDF) Overview Individualised care Education Dietary advice and interventions Blood glucose management Person-centred medicine Initial medicines How to introduce medicines Reviewing medicines Further medication Insulin-based treatments Complications Terms used in this guideline Recommendations for research Rationale and impact Finding more information and committee details Update information Overview This guideline covers care and management for adults (aged 18 and over) with type 2 diabetes. It focuses on education, dietary advice, managing cardiovascular risk, managing blood glucose levels, and identifying and managing long-term complications. For information on related topics, see our cardiometabolic disease prevention and treatment summary page . Last reviewed: 18 February 2026 We reviewed the evidence on medicines for type 2 diabetes, and made and updated recommendations for people with no relevant comorbidities and for people with common comorbidities. We also made changes to recommendations on insulin, in the context of the withdrawal of insulin products and known brand shortages. For more details, see update information . This guideline updates and replaces: NICE guidelines CG66 (published May 2008) and CG87 (published May 2009) NICE technology appraisal guidance 203 and 248 NICE evidence summaries ESNM20, ESNM26 and ESNM59. For recommendations on hypertension in people with type 2 diabetes, see the NICE guideline on hypertension in adults . Next review: This guideline will be reviewed if there is new evidence that is likely to change the recommendations. How we prioritise updating our guidance Decisions about updating our guidance are made by NICEâ€™s prioritisation board. For more information on the principles and process, see NICE-wide topic prioritisation: the manual . For information about individual topics, including any decisions affecting this guideline, see the summary table of prioritisation board decisions . Recommendations This guideline includes recommendations on: individualised care and person-centred medicine managing blood glucose levels , including HbA1c measurement and targets Initial medicines Reviewing medicines Further medication Insulin-based treatments Complications See the 2-page visual summary on factors to take into account when choosing, reviewing and changing medicines . Who is it for? Healthcare professionals Commissioners and providers Adults with type 2 diabetes, and their families and carers Guideline development process How we develop NICE guidelines Your responsibility The recommendations in this guideline represent the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement, professionals and practitioners are expected to take this guideline fully into account, alongside the individual needs, preferences and values of their patients or the people using their service. It is not mandatory to apply the recommendations, and the guideline does not override the responsibility to make decisions appropriate to the circumstances of the individual, in consultation with them and their families and carers or guardian. All problems (adverse events) related to a medicine or medical device used for treatment or in a procedure should be reported to the Medicines and Healthcare products Regulatory Agency using the Yellow Card Scheme . Local commissioners and providers of healthcare have a responsibility to enable the guideline to be applied when individual professionals and people using services wish to use it. They should do so in the context of local and national priorities for funding and developing services, and in light of their duties to have due regard to the need to eliminate unlawful discrimination, to advance equality of opportunity and to reduce health inequalities. Nothing in this guideline should be interpreted in a way that would be inconsistent with complying with those duties. Commissioners and providers have a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible. Related quality standards Type 2 diabetes in adults Next page Individualised care Back to top
